The past and future of CD33 as therapeutic target in acute myeloid leukemia
GS Laszlo, EH Estey, RB Walter - Blood reviews, 2014 - Elsevier
CD33 is a myeloid differentiation antigen with endocytic properties. It is broadly expressed
on acute myeloid leukemia (AML) blasts and, possibly, some leukemic stem cells and has
therefore been exploited as target for therapeutic antibodies for many years. The improved
survival seen in many patients when the antibody-drug conjugate, gemtuzumab ozogamicin,
is added to conventional chemotherapy validates this approach. However, many attempts
with unconjugated or conjugated antibodies have been unsuccessful, highlighting the …
on acute myeloid leukemia (AML) blasts and, possibly, some leukemic stem cells and has
therefore been exploited as target for therapeutic antibodies for many years. The improved
survival seen in many patients when the antibody-drug conjugate, gemtuzumab ozogamicin,
is added to conventional chemotherapy validates this approach. However, many attempts
with unconjugated or conjugated antibodies have been unsuccessful, highlighting the …